Christopher Ryan Sullivan sold $949k of AVTX
Chief Financial Officer at Avalo Therapeutics, Inc.. 47,000 shares at an average of $20.19, traded May 6, 2026, filed May 7, 2026.
Score components
- +22RoleCFO
- +24Trade size$949k at market
- +20Share of holdings soldSold 99% of holdings
- +15Cluster4 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -42.7%, 3m -18.2%, 6m -.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001810417-26-000010, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 6, 2026 | MOption exercise Common Stock10b5-1 | +47,000 | $8.04 | $378k | 47,423 | May 7, 2026 |
| May 6, 2026 | SOpen-market sale Common Stock10b5-1 | -13,834 | $18.55 | $257k | 33,589 | May 7, 2026 |
| May 6, 2026 | SOpen-market sale Common Stock10b5-1 | -12,347 | $19.28 | $238k | 21,242 | May 7, 2026 |
| May 6, 2026 | SOpen-market sale Common Stock10b5-1 | -2,700 | $20.76 | $56k | 18,542 | May 7, 2026 |
| May 6, 2026 | SOpen-market sale Common Stock10b5-1 | -9,219 | $21.37 | $197k | 9,323 | May 7, 2026 |
| May 6, 2026 | SOpen-market sale Common Stock10b5-1 | -8,900 | $22.57 | $201k | 423 | May 7, 2026 |
| May 6, 2026 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -47,000 | $0.00 | $0 | 116,000 | May 7, 2026 |
Related signals
Other insiders at Avalo Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 4Weak | Avalo Therapeutics, Inc. | Christopher Ryan Sullivan Chief Financial Officer | $202k 12,394 shares | -24% | |
| 12Weak | Avalo Therapeutics, Inc. | Christopher Ryan Sullivan Chief Financial Officer | $179k 10,185 shares | -20% | |
| 0Weak | Avalo Therapeutics, Inc. | Mittie Doyle Chief Medical Officer | $14k 679 shares | -1% | |
| 47Moderate | Avalo Therapeutics, Inc. | Christopher Ryan Sullivan Chief Financial Officer | $1.5M 72,725 shares | -89% | |
| 0Weak | Avalo Therapeutics, Inc. | Mittie Doyle Chief Medical Officer | $20k 1,000 shares | -2% | |
| 0Weak | Avalo Therapeutics, Inc. | Mittie Doyle Chief Medical Officer | $14k 679 shares | -1% | |
| 37Weak | Avalo Therapeutics, Inc. | Jennifer Riley Chief Strategy Officer | $52k 2,655 shares | -7% | |
| 0Weak | Avalo Therapeutics, Inc. | Mittie Doyle Chief Medical Officer | $20k 1,000 shares | -2% | |
| 0Weak | Avalo Therapeutics, Inc. | Mittie Doyle Chief Medical Officer | $93k 4,654 shares | -8% | |
| 0Weak | Avalo Therapeutics, Inc. | Mittie Doyle Chief Medical Officer | $26k 1,450 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.